Doing the math
Revenue rose nearly 13 percent to $222 million, beating the analysts’ target of $224.3 million. Net sales of diabetes drug Byetta, which Amylin co-markets with Eli Lilly and Co, rose 17 percent to $177.5 million
If the analysts expected $224.3 million in revenue and amylin delivered $222 million, how did amylin “beat the estimates”?
A good point. We corrected: GBU Editor